Skip to content

Study of the Prognosis of Patients With Heart Failure With Preserved Ejection Fraction

Study of the Prognosis of Patients With Heart Failure With Preserved Ejection Fraction

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05496439
Enrollment
172
Registered
2022-08-11
Start date
2020-03-01
Completion date
2022-07-06
Last updated
2022-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure With Preserved Ejection Fraction

Keywords

visceral fat area

Brief summary

Study of the prognosis of patients with heart failure with preserved ejection fraction

Detailed description

Obesity is an independent risk factor for heart failure with preserved ejection fraction (HFpEF), however, the impact of visceral fat area (VFA) in patients with HFpEF is unclear. According to established process of patients' selection, a total of 172 patients whose mean age was 72 years were included in this study, and the median follow-up duration was 395.5 days(interquartile range: 207.5 to 535.5 days). All patients were divided into two groups based on the best cut-off value of VFA, and the primary outcome of this study was all-cause death in patients with HFpEF. The aim of this study was to clarify whether VFA has prognostic value in patients with HFpEF by Kaplan-Meier analysis and cox analysis.

Interventions

None listed

Sponsors

Chongqing Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult aged \>=18years old; 2. Diagnosed with HFpEF.Diagnostic criteria including: 1)left ventricular ejection fraction ≥50%; 2)with the symptoms and/or signs of heart failure; 3)BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL; 4)at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction

Exclusion criteria

1. Age \<18 years old; 2. LVEF less than 45% at any time; 3. cancer diagnosis.

Design outcomes

Primary

MeasureTime frameDescription
deathThe median follow-up time of 395.5 days(interquartile range: 207.5 to 535.5 days)all-cause death

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026